Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis

Top Page

Clinical Laserthermia Systems AB Class B

(Nasdaq OMX AB:CLS.B)

Select Model

Rating:43Neutral

Price Target:SEK 2.00▲(13.64% Upside)

Action:reiterated

Date:08/03/26

The score is held down primarily by very weak operating performance (declining revenue, negative margins, and substantial losses) and continued cash burn (negative operating and free cash flow). Technicals further weigh on the outlook as the stock trades well below major moving averages. A debt-free balance sheet provides some risk reduction but is not enough to offset weak fundamentals.

Positive Factors

Debt-free balance sheetA debt-free capital structure materially reduces refinancing and interest risks, giving management flexibility to prioritize commercialization or R&D. Over months this improves solvency and lowers fixed financing costs, providing runway to execute a turnaround without near-term debt obligations.

Negative Factors

Declining revenue and negative marginsSustained revenue decline and a shift to negative gross margins indicate persistent under-absorption of fixed costs, pricing or mix pressure, and weak demand. These dynamics make achieving sustainable profitability difficult without durable volume recovery or structural cost reductions.

Clinical Laserthermia Systems AB Class B (CLS.B) vs. iShares MSCI Sweden ETF (EWD)

Market Cap: SEK 85.39M
Dividend Yield: ―
Average Volume (3M): 65.19K
Price to Earnings (P/E): -1.3
Beta (1Y): 0.39
Revenue Growth: -47.42%
EPS Growth: 44.01%
Country: Sweden
Employees: 13
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Specialties

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company Description

Clinical Laserthermia Systems AB (publ) engages in the development of treatment tools for diseased tissue under the TRANBERG brand in Sweden. It offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. The...

How the Company Makes Money

CLS generates revenue primarily by commercializing its laserthermia platform, which typically involves (1) sales of capital equipment (the laser/monitoring system installed at hospitals/clinics), (2) recurring sales of procedure-related consumables a...

Clinical Laserthermia Systems AB Class B Financial Statement Overview

Summary

Overall financial health is weak: revenue declined ~12% in TTM and profitability is deeply negative with gross margin turning negative. Cash flow is a major risk with materially negative operating and free cash flow. The balance sheet is a relative positive (zero reported debt and positive equity), but persistent losses and asset contraction keep the financial performance score low.

Income Statement

18Very Negative

Balance Sheet

62Positive

Cash Flow

24Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	12.56M	17.49M	18.78M	8.27M	6.27M	2.25M
Gross Profit	-4.10M	-29.00M	10.42M	3.00M	-2.79M	-3.63M
EBITDA	-37.95M	-26.41M	-44.76M	-68.41M	-57.84M	-57.05M
Net Income	-39.49M	-41.61M	-47.62M	-79.79M	-70.66M	-63.62M
Balance Sheet
Total Assets	66.57M	76.49M	78.56M	57.73M	49.51M	66.74M
Cash, Cash Equivalents and Short-Term Investments	3.87M	21.55M	22.51M	15.33M	10.59M	31.17M
Total Debt	0	0	224.00K	454.00K	30.68M	273.50K
Total Liabilities	22.07M	10.00M	12.88M	14.20M	41.64M	45.55M
Stockholders Equity	47.84M	69.67M	68.72M	45.77M	9.22M	21.79M
Cash Flow
Free Cash Flow	-32.35M	-36.00M	-58.92M	-71.95M	-71.25M	-66.73M
Operating Cash Flow	-25.04M	-33.20M	-56.45M	-66.45M	-70.69M	-66.17M
Investing Cash Flow	-7.31M	-2.80M	-7.47M	-5.50M	-886.00K	-408.00K
Financing Cash Flow	20.02M	35.04M	71.10M	76.69M	61.84M	85.88M

Clinical Laserthermia Systems AB Class B Technical Analysis

Technical Analysis SentimentNegative

Last Price1.76

Price Trends

50DMA1.83Negative

100DMA2.27Negative

200DMA3.80Negative

Market Momentum

MACD-0.02Negative

RSI44.80Neutral

STOCH65.07Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Negative. The current price of 1.76 is below the 20-day moving average (MA) of 1.78, below the 50-day MA of 1.83, and below the 200-day MA of 3.80, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 44.80 is Neutral, neither overbought nor oversold. The STOCH value of 65.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:CLS.B.

Clinical Laserthermia Systems AB Class B Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

SE:CLS.B against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:RAY.B	67Neutral	SEK 6.95B	32.66	22.81%	1.97%	1.42%	10.40%
SE:PAX	60Neutral	SEK 1.54B	-303.85	-1.22%	―	34.05%	-144.96%
SE:CRAD.B	58Neutral	SEK 783.39M	16.48	13.23%	0.43%	-8.76%	103.87%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SE:SPAGO	43Neutral	SEK 32.09M	-0.85	-106.23%	―	-97.37%	25.28%
SE:CLS.B	43Neutral	SEK 85.39M	-1.30	-66.41%	―	-47.42%	44.01%
SE:SPEC	40Underperform	SEK 20.68M	-0.12	-57.15%	―	―	16.02%

* Healthcare Sector Average

Performance Comparison

SE:CLS.B and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SE:CLS.B	Clinical Laserthermia Systems AB Class B	1.76	-5.87	-76.93%
SE:PAX	Paxman AB	66.30	-1.10	-1.63%
SE:RAY.B	RaySearch Laboratories AB Class B	202.80	-16.56	-7.55%
SE:SPEC	SpectraCure AB	0.01	-0.13	-90.21%
SE:CRAD.B	C-Rad AB Class B	23.20	-9.80	-29.69%
SE:SPAGO	Spago Nanomedical AB	0.04	-0.11	-72.79%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Aug 03, 2026

Clinical Laserthermia Systems AB Class B AI Stock Analysis

Top Page